SU1147029A1 - Method of influenza prophylaxis - Google Patents
Method of influenza prophylaxis Download PDFInfo
- Publication number
- SU1147029A1 SU1147029A1 SU823500455A SU3500455A SU1147029A1 SU 1147029 A1 SU1147029 A1 SU 1147029A1 SU 823500455 A SU823500455 A SU 823500455A SU 3500455 A SU3500455 A SU 3500455A SU 1147029 A1 SU1147029 A1 SU 1147029A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- influenza
- vaccine
- protective effect
- increase
- prevention
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
СПОСОБ ПРОФИЛАКТИКИ ГРИППА путем интраназального введени противогриппозной живой вакцины, от- личающийс тем, что, с целью повьппени защитного эффекта, ввод т вакцину, содержащую вирусы ;гриппа типа А/47/25/1/H1N1/ и A/47/7/2/H3N2/, вз тые в равных соотношени х. сл сMETHOD OF PREVENTION OF INFLUENZA by intranasal administration of a live influenza vaccine, distinguished by the fact that, in order to increase the protective effect, a vaccine containing viruses of influenza A / 47/25/1 / H1N1 / and A / 47/7/2 is administered (H3N2), taken in equal ratios. cl
Description
4four
о о ;0 Изобретение относитс к медици . и касаетс профилактики гриппа. Целью изобретени вл етс пов шение защитного эффекта. Способ иллюстрируетс следующи примером. Вакцину дл профилактики детей получают следующим образом. Каждым рекомбинантным штаммом заражают отдельные партии 10-12дневных развивающихс куриных эмб рионов. Через 48 ч инкубации при 32°С из зараженных эмбрионов каждой партии собирают аллантоисную вируссодержащую жидкость в отдель ные емкости, после чего смешивают в равных объемах в дозе 10 ЭИДуц и разливают в ампулы по 4,0 мл. Содержимое ампулы подвергают лиофилизации (вакуумна сушка) , затем ампулы запаивают-. Перед вакцинацией сухой материал 292 развод т до исходного объема.Вакцину ввод т интраназально. В качестве вакцинных штаммов используют штаммы 47/25/1/H1N1/ и 47/7/2/H3N2/. Дл приготовлени вакцины могут быть использованы два или несколько живых рекомбинантов, имеющих сходный состав генов, кодирующих неповерхностные белки и полученных на основе единого вирусадонора аттенуации. Иммуногенность вакцины: иммуногенность к вирусу HlNl составл ет 93,2%, к вирусу H3N2 - 76,7%; Средние геометрические титры 69,0 и 45,0, кратность прироста 8,6 и 7,5 соответственно. При использовании данной вакцины вырабатываетс защитный эффект одновременно к двум .актуальным штаммам.o o; 0 The invention relates to medicine. and prevention of influenza. The aim of the invention is to increase the protective effect. The method is illustrated by the following example. A vaccine for the prevention of children is prepared as follows. Each recombinant strain is infected with individual batches of 10–12 days old developing chicken embryos. After 48 h of incubation at 32 ° С, the allantoic vaccinated liquid is collected from separate embryos of each batch into separate containers, then mixed in equal volumes at a dose of 10 EIDutz and poured into 4.0 ml ampoules. The contents of the ampoule is subjected to lyophilization (vacuum drying), then the ampoules are sealed-. Before vaccination, dry material 292 was diluted to its original volume. The vaccine was administered intranasally. 47/25/1 / H1N1 / and 47/7/2 / H3N2 / are used as vaccine strains. For the preparation of a vaccine, two or more living recombinants can be used that have similar gene composition, coding for non-surface proteins and are derived from a single viral donor attenuation. Immunogenicity of the vaccine: immunogenicity to the HlNl virus is 93.2%, to the H3N2 virus - 76.7%; The geometric mean titers are 69.0 and 45.0, the growth rate is 8.6 and 7.5, respectively. When using this vaccine, a protective effect is developed simultaneously to two actual strains.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU823500455A SU1147029A1 (en) | 1982-07-23 | 1982-07-23 | Method of influenza prophylaxis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU823500455A SU1147029A1 (en) | 1982-07-23 | 1982-07-23 | Method of influenza prophylaxis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1147029A1 true SU1147029A1 (en) | 1986-01-30 |
Family
ID=21032116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU823500455A SU1147029A1 (en) | 1982-07-23 | 1982-07-23 | Method of influenza prophylaxis |
Country Status (1)
| Country | Link |
|---|---|
| SU (1) | SU1147029A1 (en) |
-
1982
- 1982-07-23 SU SU823500455A patent/SU1147029A1/en active
Non-Patent Citations (1)
| Title |
|---|
| № на живую гриппозную вакцину дп детей лет № от 15.10.70 (прототип). * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wiktor et al. | Cultivation of rabies virus in human diploid cell strain WI-38 | |
| Qiao et al. | Protection of chickens against highly lethal H5N1 and H7N1 avian influenza viruses with a recombinant fowlpox virus co-expressing H5 haemagglutinin and N1 neuraminidase genes | |
| Donnelly et al. | Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus | |
| AU2011234264B2 (en) | Excipients for stabilising viral particles, polypeptides or biological material | |
| ES2323490T3 (en) | PROCEDURE OF PRODUCTION OF BIOLOGICAL AGENTS IN A CROP MEANS WITHOUT PROTEINS. | |
| US4552758A (en) | Human use of avian-human reassortants as vaccines for influenza A virus | |
| US6136321A (en) | Method of inactivating lipid-enveloped viruses | |
| US4338296A (en) | Influenza virus and process of producing a vaccine therefrom | |
| Shi et al. | Evaluation of recombinant fowlpox virus expressing infectious bronchitis virus S1 gene and chicken interferon-γ gene for immune protection against heterologous strains | |
| FI59535C (en) | FOERFARANDE ATT TILLVERKA LEVANDE VIRUSVACCIN FOER NEWCASTLE-SJUKDOM | |
| US4318903A (en) | Live influenza virus vaccine and the preparation thereof | |
| Russell et al. | Cell cooperation in antibody responses to influenza virus. I. Priming of helper T cells by internal components of the virion | |
| US3953592A (en) | Live influenza virus vaccines and preparation thereof | |
| Kong et al. | Supplementation of H7N9 virus-like particle vaccine with recombinant epitope antigen confers full protection against antigenically divergent H7N9 virus in chickens | |
| SU1147029A1 (en) | Method of influenza prophylaxis | |
| Wang et al. | Enhanced cross-lineage protection induced by recombinant H9N2 avian influenza virus inactivated vaccine | |
| US20240398930A1 (en) | A vaccine for coronavirus and influenza virus, and method for preparation thereof | |
| NL8005577A (en) | METHOD FOR PREPARING A VACCINE. | |
| CA1152895A (en) | Process for the preparation of novel influenza virus strains and influenza virus vaccines containing them | |
| US3897549A (en) | Herpes simplex type 2 virus vaccine and method of production and use | |
| US3962423A (en) | Live influenza type B virus vaccines and preparation thereof | |
| US6337073B1 (en) | Intranasal yellow fever vaccination | |
| RU2340671C1 (en) | Strain of virus of flu a/17/wisconsin/05/84 (h3n2) for manufacture of live influenzal intranasal vaccine for adults and children | |
| Johansson et al. | Influenza vaccine strain selection: equivalence of two antigenically distinct haemagglutinin variants of 1989 H3N2 influenza A virus in protection of mice | |
| Kieny et al. | Development of animal recombinant DNA vaccine and its efficacy in foxes |